Quick Therapy, Inc., declared that this has successfully terminated two key clinical tests in development company new, progressive low-dose, as only-weekly, contraceptive patch, which company refers its internal code of the product AG-200-15. 2b Safety of the Phase and efficiency study successfully met primary endpoint of the suppression to ovulations, governing the cycle and bezopasnosti. pharmacokinetic Analysis (PK) demonstrated estrogen level comparable to well-installed, low-dose spoken contraceptive, LEVLEN. Was Not no serious disadvantage event in also analysis. With successful pharmacokinetic and Phase 2b safe and results of the analysis to efficiency, Company will discuss their own plans of the Phase 3 for AG-200-15 with Food and Administration Medicine.
Daniel R. Mishell, M.D., Professor in Obstetrics and Gynecology Division in University South Californium, and member of the Scientific Consulting Advice Quick, commented, “Successful termination 2b safety of the Phase and analysis to efficiency is an important forward of the step in check of safety and efficiency Quick important, new low-contraceptive patch of the dose. Good while, OB/GYN’s recommended low-dose spoken contraceptive their patient, considering based hormone contraceptive. If it is shown to be safe and efficient, low-dose, as only-weekly contraceptive patch must be natural and it is necessary addition in hormonal- contraceptive and alternative to as only-daily spoken contraceptive.”
Thomas Rossi, Ph.D., President Quick and GENERAL MANAGER, given explanation on first-class data, ” purpose to conduct these studies in that to demonstrate, which our product delivers approaching, low dose estrogen, and efficient dose progestin, levonorgestrel. We are much made happy clinical result, what, in addition to help we are chosen optimum dose for our program of the Phase 3, also demonstrate, which our patch gives the reliable adhesion and is well tolerated when shabby for 7 days. Founded in these result, we were capable be chosen AG-200-15 as our candidate for Phase 3 developments. We hope to discuss our results with and our plan of the Phase 3.”
Analysis Pharmacokinetic
pharmacokinetic Analysis was open-label, mixed, comparative, single-centre, two periods by intersection-on analysis with 39 patients that valued two contraceptive patches to see if system buy levitra opening ethinyl estradiol (EE) and levonorgestrel (LNG), were comparable to low-dose spoken contraceptive, LEVLEN. As it is expected, as EE so and opening LNG time both patch were less than LEVLEN and corresponding to level targeted company.
2b Analysis of the Phase
In this much-Phase of the cycle 2b safe and study to efficiency 123 womans, Company studied the patch with other estrogen and progestin dose for three cycles to identify the mode, providing best efficiency (as it is demonstrated by suppression to ovulations), governing the cycle and tolerability in the most low hormonal dose. The First-class results from test shown was a clear dose-answer to suppression of the ovulations and governing the cycle. AG-200-15 provided the most great suppression to ovulations by best governing the cycle three modes studied.
About Product Quick
Quick low-contraceptive patch of the dose offer the womans suitable, as only-form of the weekly birth control. Much womans prefer the weekly patch on have to remember to take the pill daily. The Company low-dose, patented, circle, softly, and flexible patch delivers 60 percents less estrogen than single marketed patch available today, Ortho EVRA. The New market study was conducted Quick in 2008 with aproximately 1,000 womans reproductive age to select, which more, than 30 percents of the womans not satisfied their current contraceptive methods. Besides, extensive majority of these womans found Quick low-address the contraceptive patch of the dose and over 50 percents must talk with their doctor about use this. It Is Expected that Quick low-contraceptive patch of the dose will fill significant need in $6 billionth global ($2.5 USA) hormonal contraceptive market.
About Estrogen
Estrogen is Bound determined general side effect such as, breast tenderness, bloat/weight of the increase and sicknesses. Suppose that These side effects are conditioned level hormone put(deliver)ed in blood flow, with more high level estrogen particularly. In little rare events, high estrogen level ed to be connected with serious, heartily side effect in some woman. Consequently, low doses estrogen in hormonal contraceptions desirable.
According to labeling, women, used Ortho EVRA are subject to to beside 60 percents more estrogen than if they used typical birth control a pill. The Raised level estrogen can enlarge the risk blood clot, which lead to add the precautionary measure to Ortho label EVRA’s.
About Quick Therapeutics, Inc.
Quick Therapy privately suspended, pharmaceutical company to professions were focused in development progressive woman healthcare products. Historically, woman healthcare unique possibilities of the market offers in company with proved by expert operation in clinical development, plenipotentiary deal, transdermal supply medicine and experience to commercializations.
The Investors of the current enterprise Quick include TL Enterprise, Capital Novitas (the Partners of the Early Stage previously POPE(PA)S), Investments ProQuest, and Company Hillman. The Company has raised the total $35 million in enterprise, financing to date.